NYU's Dr. Judith Hochman Wins 2025 Heart Association Research Award

Dr. Judith S. Hochman, a distinguished cardiologist and senior associate dean at NYU Grossman School of Medicine, will receive the prestigious 2025 Research Achievement Award from the American Heart Association during their Scientific Sessions 2025 in New Orleans. The award recognizes her decades of groundbreaking cardiovascular research that has directly influenced global clinical practice. Dr. Hochman's leadership roles include founding director of NYU's Cardiovascular Clinical Research Center, founding co-director of NYU Langone Health's Clinical and Translational Science Institute, and Harold Snyder Family Professor of Cardiology. The award will be presented by Dr. Stacey E. Rosen, the American Heart Association's 2025-2026 volunteer president, who praised Dr. Hochman as a "visionary leader" whose work has "directly impacted patient care across the full spectrum of ischemic heart disease."

Dr. Hochman's most impactful research includes serving as principal investigator for three landmark international trials that transformed cardiology practice. The Occluded Artery Trial (OAT) investigated late angioplasty in stable post-myocardial infarction patients, while the SHOCK Trial established the survival benefit of early revascularization for patients with cardiogenic shock after acute MI, reducing mortality by 13 absolute percentage points. Her most recent work, the ISCHEMIA trial, compared invasive versus conservative treatment for stable coronary artery disease and found significant quality-of-life improvements for patients with angina receiving invasive treatment. These trials led to revised clinical guidelines from the American Heart Association/American College of Cardiology and other international medical organizations, fundamentally changing how cardiovascular care is delivered worldwide.

Beyond her revascularization research, Dr. Hochman has been a trailblazer in women's cardiovascular health, pioneering studies on sex differences in acute coronary syndromes through the TIMI IIIb trial. Her work revealed the substantial incidence of women with acute coronary syndromes having no obstructive coronary disease, a concept that has gained significant attention in cardiology. Her extensive service includes roles on multiple NIH committees, FDA advisory boards, and editorial positions for major journals including Circulation, JAMA Cardiology, and European Heart Journal. Dr. Hochman expressed gratitude for the recognition, noting her "passion has always been improving outcomes for patients through rigorous science" and acknowledging the critical support from the American Heart Association and NIH throughout her career.